Servier Pharmaceuticals shared on LinkedIn:
“Partnerships have always been central to Servier’s growth strategy, helping strengthen our oncology pipeline and accelerate the delivery of innovative medicines to patients with unmet needs.
Jerome Klein, Chief Strategy and Business Excellence Officer at Servier Pharmaceuticals, joined industry leaders at LSX Congress USA to reflect on how that same partnership-first approach continues to shape our growth and expand impact as we build a rare neurology franchise.
Servier Head of Global Business Development, Frederic Scaerou, joined fellow experts on a panel discussion, ‘The Art of the Deal: Structuring Successful Biopharma Partnerships.’
Thank you to LSX for bringing together leaders from across the life sciences ecosystem to explore new opportunities to advance innovation for patients.”
Other articles about Servier on OncoDaily.